threat to distribution channels of the Company’s customers and they had to postpone their purchase orders of the Company’s products. Moreover, there were a number of incidents that adversely affected
Topic Balance by Quarter Change Q1–21 Q4–20 Q1–20 Q1–21 VS Q4–20 Q1–21 VS Q1–20 (Million Baht: MB) (MB) % (MB) % Total revenue 1,824.2 2,070.7 1,231.6 (246.5) (11.9) 592.6 48.1 Total operating expenses
first six- month of the year 2017 ended June 30, 2017 as follows: Company’s Performance (unit: million Baht ) 2017 Percentage (%) 2016 Percentage (%) Change increase (decrease) (%) Total income and other
baht or 0.4 percent compared to non-current assets as of December 31, 2018. The major change was mainly from the decreased of investment property 0.9 million baht. 2 (2) Total Liabilities Company total
results for the six-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
(3 month period) Change Revenues from hospital operations 213.42 142.19 +50.09% Gross Profit 93.30 52.15 +78.91% Profit to equity holders of the company 38.44 22.33 +72.14% Six Month Period Operational
increased by 5.40% year-over-year to Baht 47.95 million in 3Q19 from Baht 45.49 million in 3Q18. (Unit : Million Baht) 30 September 2019 (3 months period) 30 September 2018 (3 months period) Change Revenues
(Translation) Page 1 of 2 No. CBG 053/2017 14 November 2017 Re: Board resolution and change of overseas subsidiaries’ capital structure To Managing Director Stock Exchange of Thailand Reference is